NasdaqCM:NEOHealthcare
NeoGenomics (NEO): Assessing Valuation After a Sharp Three‑Month Share Price Rebound
NeoGenomics (NEO) has quietly staged a sharp recovery in recent months, with shares up around 16% over the past month and more than 55% in the past 3 months, despite still weak longer term returns.
See our latest analysis for NeoGenomics.
Even after the recent bounce, the 1 year total shareholder return is still deeply negative and the year to date share price return remains in the red. This makes the past 3 months of strong share price momentum look more like a potential turn in sentiment...